| Editor's Note: Fierce Biotech will not publish on Thursday or Friday in observance of Independence Day. We'll be back in your inbox on Monday, July 7. |
|
September 8-11, 2025 | Philadelphia, PA Join the industry's top minds at Fierce Pharma Week—where innovation, strategy, and partnerships converge. Don’t miss your chance to lead the future of pharma. Register Today.
|
|
Today’s Big NewsJul 2, 2025 |
|
Thursday, July 22, 2025 | 10am ET / 7am PT Join us to take an exciting look at the forefront of REMS transformation. Learn how leading technology, integrated strategies and operational excellence are redefining what’s possible. Gain the insights you need to reduce complexity, enhance compliance and deliver more value across the REMS lifecycle. Register now.
|
|
| By James Waldron Whether it’s drug developers being pressured to wind down or investors accused of trying to “strip mine” a biopharma, shareholder meetings are increasingly becoming verbal battlegrounds for beleaguered biotechs. |
|
|
|
By Nick Paul Taylor A drug candidate Organon hailed as perhaps its “biggest potential opportunity” has flunked a phase 2 trial, prompting the company to end clinical development of the endometriosis prospect. |
By Nick Paul Taylor A phase 3 trial of Biokin’s bispecific antibody-drug conjugate has hit at least one primary endpoint, boosting the prospects of a candidate that Bristol Myers Squibb licensed outside of China for $800 million upfront. |
Sponsored by Invest Puerto Rico With decades of excellence in biosciences, Invest PR’s CEO shares how the island is uniquely positioned to lead the reshoring movement. |
|
Discover how flow chemistry can revolutionize your chemical processes and position your business for long-term success. This insightful whitepaper explores how flow chemistry is transforming pharmaceutical manufacturing, significantly reducing waste and energy consumption. Download now.
|
|
By Gabrielle Masson Catalio Capital Management has closed its fourth venture fund with more than $400 million that will be used in part to launch two new companies. |
By James Waldron Vyne Therapeutics has given up on hopes of resuming a plaque psoriasis trial of its BET inhibitor placed on hold by the FDA, but the biotech will persevere with the candidate. |
By Darren Incorvaia Storied Japanese pharma Shionogi is upping its arsenal in the fight against antibiotic resistance. The company is paying 5 million Swiss francs ($6.3 million) upfront for a preclinical antibiotic program from BioVersys on which the two companies will work to turn into clinical candidates. |
By Noah Tong States won a partial block of mass layoffs and the HHS reorganization imposed by the Trump administration in a ruling by a federal district judge Tuesday. |
By Nick Paul Taylor Boehringer Ingelheim has breathed life into an American Lung Association campaign, providing support for a push to educate people with bronchiectasis about how to better manage the disease. |
By Zoey Becker The latest project, a sterile product manufacturing site in Brnik, will bring Sandoz' total planned and ongoing investments in Slovenia to more than $1.1 billion by 2029. |
By Dave Muoio Following a record-breaking "vote-a-rama" and tie-breaker vote, the massive bill now returns to the House where it is expected to face more scrutiny. |
Fierce podcastsDon’t miss an episode |
| | In this episode of "Podnosis," we explore how mental healthcare can evolve into a more connected, whole-person model. |
|
|---|
|
|
|
Now Available On-Demand Access this deep dive to gain valuable insights and guidance from leading industry experts on diagnostic and precision medicine testing. Register now.
|
|
| Whitepaper Presented by Blue Matter, strategic consultants in the life sciences Sponsored by Blue Matter Consulting |
| Executive SummaryBiotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster. Sponsored by: IQVIA Laboratories |
| WhitepaperWe analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
